RS62884B1 - Antitela protiv il-22r - Google Patents

Antitela protiv il-22r

Info

Publication number
RS62884B1
RS62884B1 RS20220105A RSP20220105A RS62884B1 RS 62884 B1 RS62884 B1 RS 62884B1 RS 20220105 A RS20220105 A RS 20220105A RS P20220105 A RSP20220105 A RS P20220105A RS 62884 B1 RS62884 B1 RS 62884B1
Authority
RS
Serbia
Prior art keywords
antibody
seq
antibodies
antigen
amino acid
Prior art date
Application number
RS20220105A
Other languages
English (en)
Serbian (sr)
Inventor
Christophe Frederic Jerome Blanchetot
Birgitte Ursø
Tine Skak-Nielsen
Malene Bertelsen
Der Woning Sebastian Van
Michael Saunders
Haard Johannes Joseph Wilhelmus De
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of RS62884B1 publication Critical patent/RS62884B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RS20220105A 2016-07-15 2017-07-14 Antitela protiv il-22r RS62884B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1612337.4A GB201612337D0 (en) 2016-07-15 2016-07-15 Ant-il-22r antibodies
EP17746011.0A EP3484921B1 (en) 2016-07-15 2017-07-14 Anti-il-22r antibodies
PCT/EP2017/067923 WO2018011420A1 (en) 2016-07-15 2017-07-14 Anti-il-22r antibodies

Publications (1)

Publication Number Publication Date
RS62884B1 true RS62884B1 (sr) 2022-03-31

Family

ID=56890507

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220105A RS62884B1 (sr) 2016-07-15 2017-07-14 Antitela protiv il-22r

Country Status (28)

Country Link
US (4) US10696741B2 (OSRAM)
EP (2) EP3484921B1 (OSRAM)
JP (1) JP7163275B2 (OSRAM)
KR (2) KR102571012B1 (OSRAM)
CN (1) CN109641966B (OSRAM)
AU (1) AU2017296094B2 (OSRAM)
BR (1) BR112019000788A2 (OSRAM)
CA (1) CA3024370A1 (OSRAM)
CY (1) CY1125041T1 (OSRAM)
DK (1) DK3484921T3 (OSRAM)
ES (1) ES2903412T3 (OSRAM)
GB (1) GB201612337D0 (OSRAM)
HR (1) HRP20220197T1 (OSRAM)
HU (1) HUE057615T2 (OSRAM)
IL (1) IL264262B2 (OSRAM)
LT (1) LT3484921T (OSRAM)
MX (1) MX2019000539A (OSRAM)
MY (1) MY197821A (OSRAM)
PL (1) PL3484921T3 (OSRAM)
PT (1) PT3484921T (OSRAM)
RS (1) RS62884B1 (OSRAM)
RU (1) RU2758721C2 (OSRAM)
SA (1) SA519400856B1 (OSRAM)
SG (1) SG11201900128XA (OSRAM)
SI (1) SI3484921T1 (OSRAM)
UA (1) UA125585C2 (OSRAM)
WO (1) WO2018011420A1 (OSRAM)
ZA (1) ZA201807816B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
US11834472B2 (en) * 2018-06-05 2023-12-05 Bioatla, Inc. Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN110302363B (zh) * 2019-07-04 2020-10-09 北京大学第三医院（北京大学第三临床医学院） Il-22作为制备治疗pcos药物的应用及药物制剂
WO2021241730A1 (ja) * 2020-05-29 2021-12-02 第一三共株式会社 炎症性腸疾患に対する治療用抗体
CN119836287A (zh) 2022-06-03 2025-04-15 里奥制药有限公司 Il-22r抗体的液体制剂
WO2024184333A1 (en) 2023-03-08 2024-09-12 Leo Pharma A/S Il-22r antibody for use in treating atopic dermatitis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
EP1606317B1 (en) * 2003-03-24 2010-07-28 ZymoGenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation
EA015706B1 (ru) * 2004-10-22 2011-10-31 Займоджинетикс, Инк. Моноклональное антитело или его фрагмент, связывающиеся с полипептидом il-22ra, гуманизированное антитело, полученное из указанного антитела, гибридомы, продуцирующие антитело, и применение указанного антитела
AU2006342792A1 (en) * 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
NZ599438A (en) * 2009-11-19 2013-12-20 Merck Serono Sa Humanized antibodies against human il-22ra
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
EP2791171A1 (en) * 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
EP2977386A1 (en) 2012-08-31 2016-01-27 Argen-X Nv Method for producing antibody molecules having inter-species, intra-target cross-reactivity
US10093737B2 (en) * 2013-03-01 2018-10-09 Albert Einstein College Of Medicine, Inc. HHLA2 as a novel inhibitor of human immune system and uses thereof
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies

Also Published As

Publication number Publication date
MX2019000539A (es) 2019-10-04
KR102571012B1 (ko) 2023-08-24
IL264262A (en) 2019-02-28
JP2019528046A (ja) 2019-10-10
EP4023674A2 (en) 2022-07-06
US20200157207A1 (en) 2020-05-21
WO2018011420A1 (en) 2018-01-18
US11447544B2 (en) 2022-09-20
NZ748737A (en) 2025-06-27
ES2903412T3 (es) 2022-04-01
LT3484921T (lt) 2022-01-10
CN109641966B (zh) 2022-08-23
AU2017296094A1 (en) 2018-12-13
US20200216528A1 (en) 2020-07-09
BR112019000788A2 (pt) 2019-07-02
RU2019103991A3 (OSRAM) 2021-04-29
EP3484921B1 (en) 2021-11-17
GB201612337D0 (en) 2016-08-31
US20190127459A1 (en) 2019-05-02
CY1125041T1 (el) 2023-03-24
AU2017296094B2 (en) 2024-02-01
CA3024370A1 (en) 2018-01-18
ZA201807816B (en) 2026-03-25
US20230088269A1 (en) 2023-03-23
CN109641966A (zh) 2019-04-16
IL264262B1 (en) 2024-07-01
DK3484921T3 (da) 2022-02-07
EP4023674A3 (en) 2022-10-05
SA519400856B1 (ar) 2022-10-25
JP7163275B2 (ja) 2022-10-31
UA125585C2 (uk) 2022-04-27
KR20230128137A (ko) 2023-09-01
PT3484921T (pt) 2022-01-26
KR20190026766A (ko) 2019-03-13
RU2758721C2 (ru) 2021-11-01
IL264262B2 (en) 2024-11-01
HRP20220197T1 (hr) 2022-04-29
MY197821A (en) 2023-07-18
RU2019103991A (ru) 2020-08-17
EP3484921A1 (en) 2019-05-22
SI3484921T1 (sl) 2022-02-28
US11261246B2 (en) 2022-03-01
PL3484921T3 (pl) 2022-03-28
US10696741B2 (en) 2020-06-30
HUE057615T2 (hu) 2022-05-28
SG11201900128XA (en) 2019-02-27

Similar Documents

Publication Publication Date Title
EP4296286A1 (en) Anti-gprc5d×bcma×cd3 trispecific antibody and use thereof
US20230088269A1 (en) Anti-il-22r antibodies
CN115298221A (zh) 结合b7h4的抗体
WO2015032916A1 (en) Antibodies to complex targets
US20250163182A1 (en) Enpp3 and cd3 binding agents and methods of use thereof
EP4613767A1 (en) Bispecific antibody for glypican-3 and use thereof
HK40075871A (en) Anti-il-22r antibodies
AU2024322975A1 (en) Anti-ox40l antibody and use thereof
HK40006087B (en) Anti-il-22r antibodies
HK40006087A (en) Anti-il-22r antibodies
US20230242646A1 (en) Humanized Anti-Human CD89 Antibodies and Uses Thereof
CN119301153A (zh) 结合il-17a和il-17f的抗体分子及其应用
TW202530266A (zh) 抗ＩＬ－４Ｒα抗體及其用途
WO2025185656A1 (zh) 抗pd-l1和cd40双特异性抗体及其用途
HK40083338A (en) Antibodies binding to b7h4
GB2543729A (en) Antibodies to IL-24